ArticleBioinformatics (Oxford, England)2026
A novel causality-based method for identifying drivers of breast cancer progression.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
motivationIdentifying transcriptomic factors with potential causal effects on breast cancer progression is important for understanding disease mechanisms and prioritizing therapeutic targets. However, causal-effect estimation from high-dimensional gene-expression data remains challenging because of the large number of variables and potential unmeasured confounding.
resultsWe propose CICIV, a causal inference framework that integrates PC-simple-based causal feature selection with conditional instrumental variable (CIV) representation learning. PC-simple first reduces the dimensionality of transcriptomic data by identifying candidate parent genes, after which CIV estimates and ranks their absolute causal effects. Applied to TCGA-BRCA, CICIV prioritized 40 breast cancer-related candidate genes and identified signals that were not captured by conventional correlation-based analyses. External validation using the independent METABRIC cohort showed consistent effect directions for 21 of the 40 genes, with four genes overlapping in the Top 10 and nine in the Top 20 rankings. Pathway enrichment and literature-based analyses further supported the biological relevance of the prioritized genes. AVAILABILITY AND IMPLEMENTATION: The CICIV benchmarking framework and source code are freely available at https://github.com/Zaiwen/CICIV. The software version and test data used in this study are archived at Zenodo (DOI: 10.5281/zenodo.22143976).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.